Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 11.05.2026 1 Am J Respir Cell Mol Biol 8 Am J Respir Crit Care Med 1 BMC Cancer 2 Cancer Res 8 Clin Lung Cancer 2 Clin Nucl Med 2 Eur J Cancer 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Nucl Med 2 J Surg Oncol 5 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 JAMA Oncol 4 Lung Cancer 1 Mol Cancer Ther 1 Oncologist 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Cell Mol Biol

1. DING H, Zhu X, Pan Y, Zhang Q, et al
   IGF2BP3-mediated NTSR1 m6A methylation enhances irinotecan resistance and lung adenocarcinoma malignant progression.
   Am J Respir Cell Mol Biol. 2026;74:364-374.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

2. NANA-SINKAM P
   Toward Precision in Lung Cancer: Screening, Susceptibility, and Therapeutic Resistance.
   Am J Respir Crit Care Med. 2026 May 4:aamag228. doi: 10.1093.
   PubMed        
   
   
3. MANSOURI S, Pullamsetti SS, Savai R
   Spatial niches shape early oncogene-driven lung cancer: Anatomy as destiny.
   Am J Respir Crit Care Med. 2026 Apr 15:aamag195. doi: 10.1093.
   PubMed        
   
   
4. WILLIAMS RM
   Beyond Age and Pack-Years: Consideration of Alternative Criteria to Identify Asian-Americans for Lung Cancer Screening.
   Am J Respir Crit Care Med. 2026 Apr 10:aamag192. doi: 10.1093.
   PubMed        
   
   
5. FUCITO LM, Rojewski AM, Tanoue L, Bernstein SL, et al
   NRT Starter Packs and Gain-Framed Messages to Promote Smoking Cessation in Lung Cancer Screening: A Randomized Trial.
   Am J Respir Crit Care Med. 2026 Apr 24:aamag188. doi: 10.1093.
   PubMed        
   
   
6. WAQAS A, Rasool G, Schabath MB
   Trans-omics Gene-Smoking Interactions: A New Framework for Stratifying Smoking-Related Lung Cancer Risk.
   Am J Respir Crit Care Med. 2026 Feb 25:aamag094. doi: 10.1093.
   PubMed        
   
   
7. MENG F, Xia Z, Wang S, Wang Q, et al
   Hypoxic niche drives lineage imbalance and early tumorigenesis in EGFR-mutant lung cancer.
   Am J Respir Crit Care Med. 2026 Mar 25:aamag150. doi: 10.1093.
   PubMed         Abstract available
   
   
8. CHOI E, Shusted C, Yang H, Evans H, et al
   Impact of Race and Acculturation on Lung Cancer Screening Eligibility: A Multi-Center Lung Cancer Cohort Study.
   Am J Respir Crit Care Med. 2026 Mar 19:aamag134. doi: 10.1093.
   PubMed        
   
   
9. CHENG DO, Yamada D, Azimbagirad M, Bhamani A, et al
   Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening.
   Am J Respir Crit Care Med. 2026 Mar 10:aamag104. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. YANG G, Tian L, He D, Hu J, et al
    Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.
    BMC Cancer. 2026 May 4. doi: 10.1186/s12885-026-16119.
    PubMed         Abstract available
    
    

    
    Cancer Res

11. PATEL HV, Smith AE, Chan S, Gasendo JG, et al
    The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.
    Cancer Res. 2026;86:2273-2285.
    PubMed         Abstract available
    
    
12. WANG Y, Sheng X, Yang Y, Liu C, et al
    VGF-Mediated Mitochondrial Remodeling Fuels Lung Adenocarcinoma Brain Metastasis.
    Cancer Res. 2026;86:2104-2125.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

13. KASHIZAKI F, Orii R, Watanabe S, Yumoto K, et al
    Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non-Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis.
    Clin Lung Cancer. 2026 Apr 4:S1525-7304(26)00051.
    PubMed         Abstract available
    
    
14. CATUREGLI G, Canavan M, Ayoade OF, Boffa DJ, et al
    Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer.
    Clin Lung Cancer. 2026 Apr 14:S1525-7304(26)00050.
    PubMed         Abstract available
    
    
15. OGAWA-KOBAYASHI Y, Matsumoto I, Kuramoto J, Hoshi F, et al
    Erlotinib-Induced Ocular Cicatricial Pemphigoid in EGFR-Mutated Non-Small Cell Lung Cancer: A Case Report.
    Clin Lung Cancer. 2026;27:1-4.
    PubMed        
    
    
16. LEE M, Wang S, Sun L, Halmos B, et al
    To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?
    Clin Lung Cancer. 2026;27:29-40.
    PubMed         Abstract available
    
    
17. MURAKAMI K, Shimada Y, Hamaji M, Yamanashi K, et al
    Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.
    Clin Lung Cancer. 2026;27:141-148.
    PubMed         Abstract available
    
    
18. KLEIN M, Watson D, Castro M, Kapoor S, et al
    Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2026;27:5-13.
    PubMed         Abstract available
    
    
19. LE X, Serra E, Easson K, Bellefleur R, et al
    Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.
    Clin Lung Cancer. 2026;27:41-46.
    PubMed         Abstract available
    
    
20. WANG Z, Xu Y, Chen C, Ye M, et al
    Prognostic Analysis of Different Histological Types of 2-3 cm pN0M0 Carcinoma Based on Surgical Procedure: A SEER Database Study.
    Clin Lung Cancer. 2026;27:47-53.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

21. ZHENG K, Li Q, Liu Y, Wang Y, et al
    A Primitive Endobronchial Tumor Derived by Salivary Gland on FDG PET/CT.
    Clin Nucl Med. 2026 Apr 2. doi: 10.1097/RLU.0000000000006457.
    PubMed         Abstract available
    
    
22. LIN X, Xu T, Wang R, Huang D, et al
    177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.
    Clin Nucl Med. 2026;51:518-519.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

23. BLOCKER S, Kim D, Cavalieri CC, Cannon S, et al
    Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686].
    Eur J Cancer. 2026;240:116772.
    PubMed        
    
    
24. VO-QUANG E, Campani C, Allaire M, Bouattour M, et al
    Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Eur J Cancer. 2026;239:116704.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. FAN X, Wei C, Rong M, Wang S, et al
    Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.
    Int J Cancer. 2026;159:269-279.
    PubMed         Abstract available
    
    
26. DIVER WR, Teras LR, Deubler EL, Patel AV, et al
    Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.
    Int J Cancer. 2026 May 3. doi: 10.1002/ijc.70530.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. BOGART JA, Wang X, Masters G, Komaki R, et al
    Brief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538.
    Int J Radiat Oncol Biol Phys. 2026 May 3:S0360-3016(26)00688.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. WILLMANN J, Dee EC, Hendriks LEL, Dimitriou NM, et al
    Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
    J Clin Oncol. 2026 May 5:JCO2501958. doi: 10.1200/JCO-25-01958.
    PubMed         Abstract available
    
    

    
    J Nucl Med

29. NOVRUZOV E, Mamlins E, Widjaja L, Siegmund SC, et al
    Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.
    J Nucl Med. 2026;67:687-692.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

30. 
    Correction to "Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection".
    J Surg Oncol. 2026 May 2. doi: 10.1002/jso.70137.
    PubMed        
    
    
31. 
    Correction to "Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection".
    J Surg Oncol. 2026 May 2. doi: 10.1002/jso.70140.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

32. CHEN T, Huang Y, Xue Y
    Risk stratification or treatment selection? Pathologic response and ypN status after neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00842.
    PubMed        
    
    
33. FERNANDEZ FG
    Commentary: When is enough, enough? Sublobar resection for high-risk lung cancer.
    J Thorac Cardiovasc Surg. 2026 Apr 30:S0022-5223(26)00959.
    PubMed        
    
    
34. FANG Y, Fan M, Chen H, Yu R, et al
    Surgical management of the primary tumor in stage M1a-IVA Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00907.
    PubMed         Abstract available
    
    
35. LINDEN P, Martin LW, Stiles B, Opitz I, et al
    The 2026 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Evaluation and Management of N2+ Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00899.
    PubMed         Abstract available
    
    
36. PAN H, Chen H, Xu Y, Ge Z, et al
    Optimizing Wedge Resection For Peripheral Clinical Stage IA1-2 Non-Small Cell Lung Cancer With Tumor Spread Through Air Spaces.
    J Thorac Cardiovasc Surg. 2026 May 5:S0022-5223(26)00965.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

37. DEL RIO B, Masini S, Caceres-Galvis C, Torres-Jimenez J, et al
    Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2026 May 2:103899. doi: 10.1016/j.jtho.2026.103899.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

38. FOX AH, Ward RC, Alexander M, Osarogiagbon RU, et al
    Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults.
    JAMA Oncol. 2026 May 7. doi: 10.1001/jamaoncol.2026.1080.
    PubMed         Abstract available
    
    

    
    Lung Cancer

39. ITO M, Ariyasu R, Fujishima S, Iso H, et al
    Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.
    Lung Cancer. 2026;217:109428.
    PubMed         Abstract available
    
    
40. LIANG J, Feng Y, Gui D, Zheng X, et al
    A dynamic proteomic signature for the prediction of lung Cancer: a longitudinal analysis in the UK Biobank cohort.
    Lung Cancer. 2026;217:109424.
    PubMed         Abstract available
    
    
41. IWAI C, Kimura Y, Matsui H, Fushimi K, et al
    Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study.
    Lung Cancer. 2026;217:109429.
    PubMed         Abstract available
    
    
42. KANEDA H, Tachihara M, Toi Y, Kuyama S, et al
    Phase II study of ramucirumab plus erlotinib for treatment-naive patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
    Lung Cancer. 2026;217:109432.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

43. GHAFOOR A, Zhu L, Weaver Ohler Z, El Meskini R, et al
    HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.
    Mol Cancer Ther. 2026 May 1. doi: 10.1158/1535-7163.MCT-25-1077.
    PubMed         Abstract available
    
    

    
    Oncologist

44. DRILON A, Cho BC, Camidge DR, Nagasaka M, et al
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
    Oncologist. 2026;31:oyag137.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

45. HE J, Lok CN, Yang G, He Y, et al
    A ginsenoside metabolite and its derivative target PRELID3B against lung cancer cells.
    Proc Natl Acad Sci U S A. 2026;123:e2533505123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum